Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24345675 | 1.00 | PTGER4 (0.40) | PTGER4ALDH1A1RXFP1APPNAMPT | |
| SCHEMBL13837838 | 0.82 | APP (0.38) | ALDH1A1APPNAMPTCACNA1HMEN1 | |
| SCHEMBL6952609 | 0.74 | CYP2A6 (0.53) | PTGER4ALDH1A1APPCYP2A6CACNA1H | |
| SCHEMBL29935942 | 0.74 | CYP2A6 (0.53) | PTGER4ALDH1A1APPCYP2A6CACNA1H | |
| SCHEMBL7920028 | 0.73 | CCR1 (0.43) | ALDH1A1APPNAMPTCACNA1HMEN1 | |
| SCHEMBL22778947 | 0.73 | CACNA1H (0.40) | ALDH1A1APPNAMPTCACNA1HMEN1 | |
| SCHEMBL20153853 | 0.73 | CCNC (0.48) | KMT2ASMN1; SMN2KDM4EMAOB | |
| SCHEMBL20674169 | 0.72 | APP (0.40) | ALDH1A1APPNAMPTCACNA1HMEN1 | |
| SCHEMBL3303776 | 0.72 | HSD17B10 (0.46) | ALDH1A1APPNAMPTCACNA1HMEN1 | |
| SCHEMBL22554301 | 0.72 | HPGD (0.46) | APPNAMPTCACNA1HMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| WO-2024081653-A2 | METHODS OF LOWERING MIRO2 TO TREAT NEURODEGENERATIVE DISEASES | ACUREX BIOSCIENCES CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4301759-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| WO-2022216386-A9 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022216386-A2 | T-TYPE CALCIUM CHANNEL ANTAGONISTS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGER4 1203/4885ALDH1A1 312/4885RXFP1 982/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | PTGER4 679/4885ALDH1A1 587/4885RXFP1 1092/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PTGER4 1203/4885ALDH1A1 312/4885RXFP1 982/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PTGER4 1203/4885ALDH1A1 312/4885RXFP1 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.